Biotech Values

[biophud]

Questions for board--ALNY's experimental infection model

http://biz.yahoo.com/bw/070507/20070507005609.html?.v=1

1. Is this type of experimental infection model common in infectious disease trials?
2. Does this experimetal infection model speed up clinical development of ALNY's drug? Are they looking for in vivo efficacy of RNAi prior to starting large scale trials in naturally infected patients?
3. Since ALNY already has Phase I saftey data, can't they go directly to treating patients infected with RSV?
4. Did MEDI do similar trials with Synagis?
5. Is ALNY being cautious, prior to starting trials on kids?

Comments appreciated.

biophud